AUS Peptide Supply

The early access event

Black
Friday.

20%OFF

Storewide. Starting now.

Early Black Friday

Your favourites.
An earlier saving.

Get 20% off all APS products. Sale prices are already applied, so you can get straight to shopping.

  • No discount code needed
  • Stacks with volume savings
  • Save up to 32% on eligible quantities
Shop the sale

APS products only. Partner offers excluded. Shipping and payment fees calculated at checkout.

The Research Journal.Peptide science, in perspective.
Evidence dossierPublished Updated Version 1.0

Oxytocin research guide

Cyclic nine-residue peptide and oxytocin-receptor ligand

Oxytocin molecular identity, receptor experiments and a controlled social-function trial, with clear boundaries between a peptide and a finished study formulation.

AUS Peptide Supply editorial team

01 · Identity

What the name identifies

Oxytocin is a cyclic nonapeptide with a disulfide bond linking its cysteine residues. Molecular identity, receptor activity and the performance of a formulated product are separate evidence questions. A familiar compound name does not confirm the structure or content of a supplied sample.

02 · Evidence position

What the literature can support

Foundational receptor research explains one biological target, while clinical findings depend on population and formulation. The selected large autism trial did not demonstrate a benefit on its primary social-function endpoint. That finding should not be replaced by broad claims about bonding or trust.

03 · Study-level map

Evidence and its limits

Analytical identity

Which structural features define the reference molecule?

The PubChem record identifies a nine-residue peptide with a disulfide-linked cyclic structure and an amidated terminus.

Limit: A database structure is a reference identity, not evidence that a batch has the expected structure, content or purity.

Preclinical

What did the receptor-cloning study establish?

The 1992 study described the human oxytocin receptor and an oxytocin-responsive experimental expression system.

Limit: A receptor-system response is not the same endpoint as a behavioural or clinical benefit.

Human randomised

What did the 24-week autism trial find?

The 2021 placebo-controlled trial enrolled 290 children and adolescents and found no significant between-group advantage on its primary social-withdrawal measure.

Limit: The result concerns the studied intranasal formulation and population, not every oxytocin experiment or this research material.

04 · Analytical context

Questions a batch record should answer

  1. 01Does the identity assessment address the expected disulfide-linked structure and terminal form?
  2. 02Are peptide content and biological activity measured separately, with their units stated?
  3. 03Is a formulated-product claim being distinguished from evidence for the actual research material?

05 · Boundary conditions

What this record does not establish

  • A general social or behavioural effect cannot be inferred from receptor activity.
  • Mass in milligrams is not automatically an activity-unit specification.
  • No verified APS CoA is available for the associated product at publication.

Sources checked

  1. 1.
    Oxytocin — PubChem CID 439302

    NIH PubChem · 2026 · Chemical database

  2. 2.
    Structure and expression of a human oxytocin receptor

    Kimura et al. — Nature / PubMed · 1992 · Primary study

  3. 3.
    Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder

    Sikich et al. — New England Journal of Medicine · 2021 · Primary study

Continue through the topic